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Recent observations suggest that p53 mutations are responsible
not only for growth of primary tumors but also for their dissem-
ination. However, mechanisms involved in p53-mediated control of
cell motility and invasion remain poorly understood. By using the
primary ovarian surface epithelium cell culture, we show that
conditional inactivation of p53 or expression of its mutant forms
results in overexpression of MET receptor tyrosine kinase, a crucial
regulator of invasive growth. At the same time, cells acquire in-
creased MET-dependent motility and invasion. Wild-type p53
negatively regulates MET expression by two mechanisms: (i) trans-
activation of MET-targeting miR-34, and (ii) inhibition of SP1 bind-
ing to MET promoter. Both mechanisms are not functional in p53
absence, but mutant p53 proteins retain partialMET promoter sup-
pression. Accordingly, MET overexpression, cell motility, and inva-
sion are particularly high in p53-null cells. These results identifyMET
as a critical effector of p53 and suggest that inhibition of MET may
be an effective antimetastatic approach to treat cancers with p53
mutations. These results also show that the extent of advanced
cancer traits, such as invasion, may be determined by alterations
in individual components of p53/MET regulatory network.
Transcriptional factor p53 provides integrated responses toimplement cell cycle arrest, senescence, differentiation, in-
hibition of cancer metabolism, or induction of the apoptotic cas-
cade (1). Mutations of p53 occur in about 50% of all cancers and
result in loss of its function, either by null phenotype or dominant-
negative effect. Additionally, some mutations result in new activ-
ities of p53, known as gain-of-function mutations (2). Recent
observations indicate that p53 mutations affect cell motility and
invasion, key features of metastasis (3–8). Better understanding of
mechanisms of p53-dependent effects on cell motility and invasion
should lead to development of approaches aimed toward correc-
tion of aberrant p53 signaling not only for suppressing growth of
primary tumors but also for preventing their dissemination.
A signaling conduit known to play a critical role in invasion and
metastasis is the MET pathway (9). The MET proto-oncogene
encodes a transmembrane receptor-protein tyrosine kinase, whose
overexpression is associated with poor prognosis in a broad vari-
ety of cancers (10, 11). Inhibition of MET functions has been
shown to be effective in animal models and is among the most
promising candidates for targeted therapy (10).
Previously it has been reported that MET is overexpressed in
tumors of p53-deficient mice and in Li-Fraumeni patients (12).
This observation is consistent with recent reports that MET
represents one of the common targets for the miR-34 family (13–
15). Genes encoding for the miR-34 family have been identified
as direct targets of p53 transactivation (reviewed in ref. 16). At
the same time, it has been reported that mouseMet promoter has
a putative p53 responsive element and thatMet promoter activity
is activated by p53 through DNA binding to the p53 consensus
sequence (17). Thus, the role of MET in p53-dependent sup-
pression of invasion remains uncertain.
Because many cancers are genomically unstable and separa-
tion of critical alterations from “genetic noise” may be a daunt-
ing task in cells derived from advanced stages of the disease, we
have used a model of conditional p53 inactivation in the primary
ovarian surface epithelium (OSE), transformation of which leads
to epithelial ovarian cancer (EOC) (18, 19). This system is highly
clinically relevant because p53 mutations are by far the most
frequent alterations in human high-grade serous adenocarci-
noma of the ovary (20), are detected in the stage 1 of those
cancers and in adjacent dysplastic lesions (21, 22), and their
presence correlates with metastatic potential (23). MET over-
expression is also associated with poor prognosis of EOC
patients and targeting the MET pathway has been reported to
suppress EOC in mouse models (11).
We report that MET is a critical player in p53-mediated
control of motility and invasion, and show that such control
includes miR-34–independent regulation of MET expression by
p53, in addition to earlier described MET targeting by miR-34.
Alterations in individual components of the p53/MET regulatory
network may affect the extent of cancer invasion.
Results
p53 Inactivation Leads to MET Overexpression. To evaluate imme-
diate transcriptome changes associated with p53 inactivation, we
conducted mRNA microarray analysis of primary OSE cells after
acute inactivation of p53, Rb, or both p53 and Rb concomitantly
(Fig. 1A and Fig. S1). Interestingly, in addition to the expected
targets of p53 and Rb/E2f signaling, up-regulation of the Met
proto-oncogene was detected as a consequence of p53 and p53/
Rb inactivation, but not of inactivation of Rb alone (Fig. S1).
According to qRT-PCR (Fig. 1B) and Western blot analysis (Fig.
1C), MET expression levels continued to rise for 72 h after gene
inactivation and were particularly high in neoplastic OSE cell
lines (over 40 passages) deficient for p53 (OSN2) or p53 and Rb
(OSN1). Consistently, p53 knockdown in human ovarian cancer
cells OVCA433 and colon cancer cells HCT116 carrying wild-
type p53 resulted in increased MET expression (Fig. S2A). To
examine whether MET overexpression would be detected in vivo
early after p53 inactivation, Ad-Cre was delivered to the OSE of
p53fl/flRbfl/fl Z/EG mice by transoviductal injection. Consistent
with the cell-culture experiments, elevated levels of MET were
detected in OSE cells that had Cre-loxP–mediated recombination
according to expression of EGFP reporter 72 h after Ad-Cre
administration, but Ad-Blank administration did not result in
detectable MET or EGFP expression (Fig. 1D). No morpholog-
ically detectable differences were observed between mutant and
wild-type OSE at that time (Fig. S2B).
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MET Is Essential for p53-Controlled Cell Motility and Invasion. Be-
cause increased motility and invasion are among the principal
effects of up-regulated MET signaling, those features were tested
in p53-deficient OSE cells. Compared to cells with wild-type p53,
p53-null cells showed significantly increased cell motility in wound
healing/time-lapse microscopy and migration assays, as well as
increased propensity for invasion in Matrigel chambers (Fig. 2
A–D, Fig. S3A, and Movies S1 and S2). Moreover, treatment of
cells withMET ligandHGFenhancedmigration and invasion even
further (Fig. 2 A and B). The increased motility and invasion was
accompanied by elevation of levels of phosphorylated MET (Fig.
S3B). To test the extent ofMet contributions to these properties of
p53-null cells, both genes were inactivated in OSE cells derived
from p53fl/flMetfl/fl mice. Met inactivation abrogated the motility
and invasion, but not proliferation phenotype associated with p53
inactivation (Fig. 2E and Fig. S4). Thus,MET signaling is essential
for p53-controlled motility and invasion.
p53 Has a miR-34-Independent Mechanism of MET Regulation. Con-
sistent with regulation of MET expression by p53, expression of
p53 at levels comparable to those of endogenous activation re-
sulted in decreased amounts of MET protein in both mouse
and human neoplastic ovarian cell lines, OSN2, and SKOV-3,
respectively (Fig. 3A and Fig. S5).
To test the extent of MET expression dependence on miR-34,
ovarian neoplastic cells were subjected to increasing amounts of
miR-34 precursor molecules in transient transfection experi-
ments. Maximum reduction of MET expression was observed at
30-nM concentration, with no apparent effect of further increases
in amounts of miR-34a precursor molecule (Fig. S6 A and B) or
combination of miR-34a, b, and c (15). No effect on MET pro-
moter activity was observed after transfection of the full-length
MET promoter reporter construct (pGL2-3.1MET) together with
individual miR-34 family precursor molecules (Fig. S6C). These
observations were in agreement with bioinformatics predictions
and experimental evidences that miR-34 regulates MET expres-
sion principally by targeting MET 3′UTR (reviewed in ref. 16),
However, cotransfection of miR-34a precursor together with
wild-type p53 resulted in further down-regulation of MET (Fig.
3A), suggesting that p53 may have a miR-34–independent
mechanism of MET regulation. Similar effects of p53 and miR-
34a precursor transfection on MET down-regulation were ob-
served in p53-null lung cancer cells NCI-H1299, indicating
potential significance of these observations for pathogenesis of
other types of epithelial cancers (Fig. S6D).
To directly show the presence of miR-34–independent mech-
anism of MET regulation by p53, we isolated OSE cells from mir-
34a−/−mir-34b/c−/− (triple knockout, TKO) mice, lacking the en-
tire mir-34 family of genes. As expected, OSE cells from TKO
Fig. 1. Inactivation of p53 leads to increase of MET
expression. (A) Outline of experiments. After Ad-Cre–
mediated p53 inactivation, the mRNA expression profile
was generated followed by qRT-PCR and Western blot
validation of identified targets and elucidation of their
functions by experimental testing. (B and C) Levels of
MET mRNA and protein in primary OSE cells before and
after p53 inactivation or p53 and Rb inactivation
according to qRT-PCR and Western blot analysis, re-
spectively. Neoplastic OSE cell lines (over 40 passages)
deficient for p53 (OSN2), or p53 and Rb (OSN1), have
particularly high levels of MET. qRT-PCR data: n = 4,
mean ± SD. (D) Representative examples (Upper and
Lower) of MET expression in the OSE of p53fl/flRbfl/fZ/EG
mice 72 h after exposure to either Ad-Cre (Upper) or
Ad-Blank (Lower) delivered by transoviductal intra-
bursal injection. Z/EG reporter indicates Cre-loxP medi-
ated recombination by expression of EGFP. Note
colocalization (arrows, yellow) of MET (red) and EGFP
(green) in OSE cells that underwent Cre-mediated re-
combination. Arrows indicate OSE. Double immunoflu-
orescence. DAPI counterstaining. (Scale bar, 100 μm.)
Fig. 2. MET is essential for p53 inactivation-mediated cell motility and in-
vasion. (A and B) Cell migration and invasion 24 h after p53 inactivation either
in absence or presence of 20 ng/mL HGF in the lower chamber. (C) Motility of
primary p53fl/fl OSE cells 72 h after infection with either Ad-LacZ or Ad-Cre.
Percentages (mean ± SD) of the closed-wound area 0, 12, and 24 h after the
scratch were measured by TScratch software. (D) Tracking of individual wild-
type (WT) and null p53 (Mut) cells (n = 14 each) in wound healing assay using
time-lapse microscopy followed by analysis with ImageJ multitrack software.
(E) Invasion properties of primary OSE cells isolated from p53fl/fl and p53fl/fl
Metfl/fl mice. Cells (2.5 × 104) were seeded into either control or Matrigel
inserts 24 h after Ad-LacZorAd-Cre infectionwith HGF (20 ng/mL) in the lower
chamber. Invading cells were counted after staining under the microscope
20 h afterward. Bars, SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001.
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mice showed a higher level of MET compared with wild-type
OSE cells (Fig. 3B). Reconstitution of miR-34 by transfecting
miR-34a precursor molecules resulted in down-regulation of
MET (Fig. 3C). Notably, p53 knockdown in TKO OSE cells led
to an increase of MET expression (Fig. 3D), confirming that p53
down-regulates MET expression in a miR-34–independent man-
ner, in addition to miR-34–dependent mechanism (Fig. 3E).
p53 Suppresses MET Promoter Activity. To test if MET promoter
activity can be affected by p53 through binding of p53 consensus
sequences in ovarian cells, reporter constructs containing −2619
to +353 fragments of MET upstream sequence (3.1MET) and its
shorter fragments (24) were cotransfected with p53 expression
vector into SKOV-3 (Fig. 4) and OSN2 cells (Fig. S7 A and B).
Transfection of p53 significantly suppressed the promoter activity
of the 3.1MET construct, as well as that of smaller fragments.
Even when the putative p53 responsive element was mutated
(0.65METm), p53 was still capable of repressing MET promoter
activity comparably to the repression by corresponding wild-type
promoter construct (0.65MET), indicating that the discrepancy
between a previous report (17) and our findings may be a result of
cell-type–specific effects.
To rule out the possibility that the observed effects of p53 on
MET promoter activity were caused by global transcriptional re-
pression by ectopically expressed p53, PG-13-luc and MG-15-luc
reporter constructs, containing 13 copies of wild-type p53 con-
sensus sequence and 15 copies of mutated p53 consensus se-
quence (25), respectively, were cotransfected with plasmids ex-
pressing either wild-type or DNA binding domain mutant p53.
Only wild-type p53 could activate PG-13-luc promoter activity
in SKOV3 (Fig. S7C) and OSN2 cells (Fig. S7D); all four mutant
p53 constructs were unable to activate both promoter constructs.
Furthermore, p53 has been shown to inhibit hypoxia-inducible
factor-stimulated transcription by destabilizing hypoxia-inducible
factor 1α (HIF1A), one of the prominent regulators of MET
promoter activity (26). However, p53 inactivation did not lead to
accumulation of HIF1A in OSE cells (Fig. S8A), likely because of
uneven sensitivity of different cell types to hypoxia (27). Consistent
with cell-type–specificity, OSE cells and ovarian cancer cell lines
(OVCA432, OVCA433, and OVCAR-3) did not overexpress
MET under hypoxic conditions regardless ofHIF1A accumulation
(Fig. S8B), unlike colon cancer HCT-116 cells (Fig. S8 C and D).
Another potential mechanism for p53-dependent regulation
of MET is through CD44. CD44 is known to form a multimeric
complex and cooperate with MET (28). CD44 has been also re-
cently identified as a p53 (29) and miR-34 (30) target. However,
CD44 was not among genes significantly up-regulated after p53
inactivation in gene-expression microarrays (Fig. S1). Further-
more, ectopic p53 or miR-34 expression did not affect CD44
levels in ovarian carcinoma cells (Fig. S8E).
Taken together, these results show that MET suppression by
p53 is unlikely to be to the result of global transcriptional re-
pression, HIF1A, or CD44 expression.
p53 Inhibits SP1 Binding to MET Promoter. Because p53 was able to
suppress activity of nonoverlapping promoter constructs 0.27MET
and 0.37MET, transcription-factor binding sites common for
both constructs were searched for by bioinformatics analysis.
This search identified binding sites for the SP1 transcription
factor (Fig. S7E). To test whether SP1 is required for MET
promoter activity, SKOV-3 and OSN2 cells were treated with
mithramycin A (mitA) to inhibit DNA binding of SP1 (31). MitA
treatment suppressed luciferase expression under control of
MET promoter in a dose-dependent manner, indicating that SP1
is required for MET promoter activity (Fig. 5A and Fig. S7F).
This suppression was not increased by p53 expression, indicating
that p53 and SP1 share a common molecular pathway to regulate
MET promoter activity (Fig. 5B).
Coimmunoprecipitation experiments demonstrated that either
ectopic or endogenous p53 physically interacts with endogenous
SP1 in SKOV-3 and OVCA433 cells, respectively (Fig. 5 C–E).
To test if p53 may inhibit SP1 DNA binding ability, ChIP
experiments were performed with SP1 antibody and amplicons
covering the distal and proximal region of the MET promoter,
which contain and lack SP1 sites, respectively (Fig. 5F). SP1
binding was selectively enriched on the proximal region of the
Fig. 3. p53 has a miR-34-independent mechanism of MET regulation. (A)
MET expression after transient transfection of p53 expression vector (pORF-
hp53) or miR-34a precursor molecule (30 nM) into SKOV-3 or OSN2 cells. (B)
MET expression in OSE cells derived from eithermir-34a−/−mir-34b/c−/− (TKO)
or age-matched wild-type (WT) mice. (C) MET expression in TKO OSE cells
after transfection with either scrambled microRNA (control) or 30 nM miR-
34a precursor molecules. (D) MET expression in TKO OSE cells 48 h after
transfection with either control siRNA or p53 siRNA (20 nM). (E) A diagram
of proposed miR-34–dependent and independent regulation of MET by p53.
Fig. 4. p53 suppresses MET promoter activity. (A) Promoter constructs used
in this study: 3.1 Kb humanMET promoter sequence including 5′ UTR region
(3.1MET) and its shorter fragments were cloned into pGL2-luciferase vector.
p53 putative response element (star) was mutated in 0.65METm. (B and C)
MET promoter activity after cotransfection of p53 expression vector (pORF-
hp53) with individual promoter constructs into SKOV-3 cells. Cell lysates
were harvested for estimation of luciferase activity 48 h after transfec-
tion. Note that p53 response element mutation does not abolish MET pro-
moter suppression by p53 (C). All experiments were performed in triplicates.
Bars, SD.
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MET promoter, and p53 expression resulted in significant re-
duction of SP1 binding (Fig. 5 G and H). Conversely, as expec-
ted, p53 did not affect SP1 binding to the survivin promoter (Fig.
5G), which is repressed by p53 through recruitment of chromatin
remodeling complexes (32). Consistently, in mouse OSE cells,
p53 inactivation led to an increase of SP1 binding to the corre-
sponding mouse Met promoter proximal region (Fig. 5I). Taken
together, these results show that p53 is likely to suppress MET
promoter activity through inhibition of SP1 DNA binding.
Mutant p53 Proteins Interact with SP1 and Their Effects on OSE
Motility and Invasion Depend on MET. To explore the role of mutant
p53 in Met regulation, four expression vectors encoding DNA
binding domain p53 mutants (V143A, R175H, R249S, and
R273H) were transfected withMET promoter reporter constructs
into SKOV-3 and OSN2 cells. All mutant p53 vectors suppressed
0.65MET and 0.27MET constructs, albeit less efficiently when
compared with wild-type p53 (Fig. 6 A and B, and Fig. S9 A and
B). Accordingly, the mutant p53 proteins were coimmunopreci-
pitated with SP1 (Fig. 6C), indicating that at least these common
p53 mutants retain interactions with SP1.
Cells of human ovarian cancer cell lines OVCA432 and
OVCAR-3 carrying mutant p53 did not show an increase of
already high MET levels after p53 knockdown (Fig. S9C). To
further explore the role of mutant p53 in motility and invasion,
primary OSE cells were prepared from p53+/LSLR172H and
p53+/LSLR270H mice, which contain a conditionally activated
copy of mutant p53 corresponding to human p53 R175H and
R273H hot-spot mutations, respectively. Despite overall in-
creased p53 expression after Ad-Cre infection (Fig. S10A), Met
expression increased only slightly (Fig. 6D). Although loss of
both p53 copies is sufficient to immortalize OSE cells (18),
p53+/R172H and p53+/R270H OSE cells had a very limited pro-
liferation potential and underwent senescence (Fig. S10B), con-
sistent with a previously reported phenotype of mouse embryonic
fibroblasts (MEFs) carrying the same p53 mutations (33).
Similarly to MEF immortalization after the loss of remain-
ing wild-type copy of p53, OSE cells from p53fl/LSLR172H and
p53fl/LSLR270H mice were easily immortalized after Ad-Cre in-
fection. In these cells, levels of Met expression were higher than
those in cells heterozygous for mutant p53 but less than those in
a p53-null background (Fig. 6E). Cells carrying mutant R172H or
R270H p53 also displayed increased cell invasion, although at
a lesser extent than p53 null cells (Fig. 6F). Similarly to observa-
tions in p53-null cells, deletion of Met abrogated increased mi-
gration and invasion associated with mutant R172H or R270H
p53 (Fig. 6G and Fig. S10C).
Discussion
Our work shows that p53 controls the expression of the proto-
oncogene MET by two mechanisms, consisting of suppression of
MET on the transcriptional level via promoter repression and on
the posttranscriptional level via transactivation of miR-34.
Contrary to a previous report (17), we were unable to find any
canonical or novel p53 binding sites selectively responsible for
either activation or repression of MET promoter. At the same
time, the results of our promoter analysis, together with coim-
munoprecipitation and ChIP assays, provide support for
a mechanism of MET transcriptional repression based on in-
hibition of SP1 binding to DNA through physical interactions
between p53 and SP1 rather than on direct promoter-binding by
p53. Consistent with this possibility, it has been previously
reported that SP1 activates MET promoter activity (34, 35) and
interacts with wild-type (36, 37) and mutant p53 (2). Further-
more, p53 inhibits SP1 DNA binding to the HIV-LTR and
MGMT promoter in vitro (38, 39).
Either lack of p53 or expression of its mutant forms abrogates
miR-34 transactivation of miR-34 (16). Therefore, both types of
Fig. 5. p53 inhibits SP1 binding to MET promoter. (A)
Effect of mithramycin A (mitA) on MET promoter ac-
tivity. SKOV-3 cells were pretreated with mitA 1 h be-
fore transfection with 0.27MET promoter construct. (B)
Individual and combined effects of mitA (100 nM) and
p53 expression on 0.27MET promoter activity in SKOV-3
cells. Bars, SD (n = 3). ***P < 0.001. (C–E). Detection of
p53 and SP1 binding by coimmunoprecipitation. Either
control (pORF, mock) or p53 expression vector (pORF-
hp53, p53) was transfected into SKOV-3 cells. Forty-
eight hours after transfection, cell lysates were immu-
noprecipitated with SP1 (C) or p53 (D) antibodies fol-
lowed by Western blotting with p53 or SP1 antibodies,
respectively. (E) OVCA433 cell lysates were immuno-
precipitated with SP1 antibodies, followed by Western
blotting with p53 antibody (Upper, IP:SP1). Samples of
the same lysates were used for Western blotting with
SP1 or p53 antibody before precipitation (Lower, WB).
(F) Design of ChIP assays. The proximal region of MET
promoter contains three potential SP1 binding sites
(gray oval shapes), but the distal region has none.
Arrows, primers for PCR amplified regions. (G and H).
Qualitative (G) and quantitative (H) analyses of ChIP
assays with SP1 antibody and the distal and proximal
region of MET promoter. ChIP assay was performed
48 h after transfection of p53 vector into SKOV-3 cells.
Two-percent input control was loaded for comparison.
The results are representative of three independent
experiments. *P = 0.0182. Bars, SD. (I) Analysis of mouse
Met promoter region corresponding to the proximal
region of human MET promoter. ChIP assay was per-
formed 48 h after either Ad-LacZ or Ad-Cre infection of
OSE cells from p53fl/fl mice.
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mutations result in elevation of miR-34–dependent MET expres-
sion. However, our study shows that unlike null mutations, mutant
p53 protein retains MET promoter-suppressive function, albeit
to a lesser degree than wild-type p53. Consistent with the lesser
extent of MET expression, cells expressing mutant p53 display
a lowerMET-dependent motility and invasion compared with null
mutants. These findings suggest that specific alterations in in-
dividual components of the p53/MET signaling network may
modulate the course of pathological process. Consistent with this
possibility, the poorest prognosis of p53 null mutations has been
reported in some types of neoplasms, including ovarian, lung, and
breast cancers (40–42).
Recent studies indicate that lack of p53 versus expression of
mutant p53 proteins may have a different impact on motility and
invasion in the context of particular cell types, as well as addi-
tional genomic alterations. Our observations of increased mo-
tility and invasion by p53-null OSE cells are consistent with
previous studies that have shown comparable effects in p53-null
immortalized fibroblasts and MEFs (3, 4). Similarly, non-small-
cell lung carcinoma line NCI-H1299 cells harboring a p53-null
mutation have been reported to migrate faster than those ex-
pressing R175H mutant p53 (43).
At the same time, some investigators have reported that mu-
tant p53 protein but not null p53 mutations may drive cell mo-
tility and invasion by promoting integrin recycling (5), by forming
a complex with Smad to oppose p63-mediated control of putative
metastasis suppressors Sharp-1 and cyclin G2 (6) or by stabilizing
the invasion promoter Slug (7). Consistent with cell-type speci-
ficity of p53 effects, mice expressing mutant p53 develop a more
diverse spectrum of neoplasms compared with null mutants (33).
Interestingly, in line with observations by Grugan et al. (44),
knockdown of mutant p53 in ovarian carcinoma cells did not
change levels of MET expression. This observation is at variance
with our results on primary OSE cells carrying a conditional
mutant p53 allele, which may indicate that established cancer
lines and neoplastic cells at advanced cancer stages develop
additional mechanisms ensuring MET signaling in cells carrying
mutant forms of p53 protein. Assessment of primary ovarian
cancer cells should address this problem in future studies. It
should be also of interest to evaluate p53/MET signaling in the
fallopian tube epithelium, another potential cell of origin of
serous adenocarcinoma of the ovary (45, 46).
There are indications that some additional genetic or epige-
netic alterations are required for stabilization and accumulation
of mutant p53, thereby leading to a gain-of-function phenotype
(47). In agreement with this possibility, our results in primary
OSE from p53+/R172H or p53+/R270H mice, as well as studies by
others in MEFs with the same genotypes (33), show that cell
immortalization is acquired only after the loss of the remaining
wild-type copy of p53. Consistently, Adorno et al. (6) were able to
observe increased migration of cells expressing mutant p53 only in
combination with HRAS and TGF-β signaling. Notably, RAS
mutations are extremely rare in high-grade serous ovarian carci-
noma (23).
Development of therapies aimed at correction of the p53
pathway remains among the most coveted goals in cancer research
(48). Importantly, our experiments have demonstrated that MET
is a critical component of motility and invasion in cells either
lacking p53 or expressing its mutant forms. Therefore, treatment
of cancers with p53 mutations is likely to benefit from therapeu-
tics aimed at MET, such as small targeting molecules (10). This
finding is of particular significance because, despite successful
outcomes in cell culture and animal in vivo experiments, direct
reintroduction of the p53 gene failed in clinical trials, including
EOC (49). Our study also indicates that approaches aimed at in-
direct elimination of mutant p53 protein (e.g., by p53 siRNA)
should be avoided in cancers with an active p53/MET signaling
network. The in-depth understanding of mechanisms by which p53
regulates MET in the context of different cell types, as well as
specific p53 mutations, may be essential for future development of
individualized therapeutics.
Materials and Methods
Experimental Animals. The origin and genotyping of mice with conditional
alleles of wild-type and mutant p53, Rb1, Met, and reporter genes are de-
scribed in the SI Materials and Methods. The mir-34a−/− mice generated in
H.H.’s laboratory and mir-34b/c−/− mice generated in A.Y.N.’s laboratory
were crossed to obtain mir-34a−/−mir-34b/c−/− mice. All mice were main-
tained identically following recommendations of the Cornell Institutional
Laboratory Animal Use and Care Committee.
Cell Culture. Derivation and culture conditions of primary mouse OSE cells,
established mouse OSE cell lines (OSN1 and OSN2), and human cancer cell lines
SKOV-3, OVCAR-3, OVCA432,OVCA433, NCI-H1299, andHCT116, aswell as pro-
liferation and senescence assays, are described in SI Materials and Methods.
Conditional Gene Inactivation and mRNA Microarray Profiling Studies. Primary
OSE cells carrying conditional gene alleles were passaged three times and
treated with recombinant adenoviruses essentially as described previously
(18, 19). Cells were collected two passages after infection and processed for
Fig. 6. Contribution of mutant p53 protein to OSE motility and invasion
depends onMET. (A and B) Effects of wild-type andmutant p53 (V143A, R175H,
R249S, and R273H) on the activity of 0.65MET (A) and 0.27MET (B) promoter
fragments in SKOV-3 cells. (C) Detectionof SP1 binding towild-type andmutant
p53 after transient transfection into SKOV-3 cells. (D and E) Met expression in
OSE cells from p53+/LSLR172H, p53+/LSLR270H, p53fl/LSLR172H, and p53fl/LSLR270H mice
48 h after Ad-Cre infection. qRT-PCR, n = 3, mean ± SD. (F) Invasion of OSE cells
from p53fl/fl, p53fl/LSLR172H and p53fl/LSLR270Hmice 24 h after Ad-Cre infection. (G)
Met inactivation abrogates increased invasion of OSE cells containing p53
R172H mutation. Bars, SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001.
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mRNA isolation and assessment of mRNA profiles as described in SI Materials
and Methods.
Transinfundibular Administration of Adenovirus, Collection of Histological
Materials, and Immunohistochemistry. All procedures were performed as
described previously (18). The detailed protocol MET/EGFP double immu-
nofluorescence is provided in SI Materials and Methods.
Wound Healing, Time-Lapse Microscopy, Migration, and Invasion Assay. For
wound-healing assay, OSE cells were infectedwith adenovirus and cultured in
a 10-cm gelatin-coated dish to confluence. Cells were scraped with a p200 tip,
and fresh medium supplemented. Digital images of the wound were taken at
0, 12, and 24 h after scraping. Analyses of the wound-closure and time-lapse
microscopy are described in SI Materials and Methods. Migration and in-
vasion assays were performed as described in ref. 15.
Promoter Activity Analysis and Transfection, Quantitative Real-Time RT-PCR,
Coimmunoprecipitation, Western Blotting, ChIP Assays, and Statistics. All
procedures were performed according to establishedmethods as described in
SI Materials and Methods.
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